MedTrace Logo

Cardiac Structure and Function in MPS

NCT07361536 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2026-01-26

No results posted yet for this study

Summary

The purpose of this study is to better understand how heart and blood vessel problems develop in people with Mucopolysaccharidosis (MPS). The investigators are looking at certain substances in the body called GAGs and proteoglycans to see how they affect the heart. The investigators also want to find reliable blood and urine markers that can help us track heart health and guide future treatments.

This study aims to answer two main questions:

1. Do people with MPS show faster changes in their blood vessels over time (such as thickening or stiffening of the carotid artery) compared to people without MPS?
2. Do people with MPS have higher levels of certain proteins in their blood (such as clusterin and inflammatory markers) that are linked to blood vessel changes?

What participants will do?

Participants will complete the following tests once a year for 4 years:

* Carotid ultrasound: an imaging test that looks at the blood vessels in the neck.
* Echocardiogram: an ultrasound of the heart.
* Blood draw
* Urine collection

These tests help the investigators track changes in heart and blood vessel health over time.

Conditions

  • MPS I
  • MPS IV A
  • MPS - Mucopolysaccharidosis
  • MPS IVA

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Children's Hospital of Orange County

    lead OTHER

Eligibility

Min Age
0 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2030-04-30
Completion
2030-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07361536 on ClinicalTrials.gov